NCT01553942 - Afatinib With CT and RT for EGFR-Mutant NSCLC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions

Lung Cancer

Interventions

DRUG

Afatinib

induction phase-two 4 week cycles. consolidation phase-twenty six 4 week cycles

RADIATION

Radiation

Daily, Monday-Friday

DRUG

Cisplatin

Day 1 of each cycle, IV infusion over 60 minutes

DRUG

Pemetrexed

Day 1 of each cycle, given as IV infusion over 10 minutes after cisplatin infusion

PROCEDURE

Surgery

Surgery to remove tumor

Trial Locations (2)

Dana-Farber Cancer Institute, Boston

Massachusetts General Hospital, Boston

All Listed Sponsors

lead

Massachusetts General Hospital

OTHER